The U.S. may have reopened too quickly.

In fact, according to former US FDA Commissioner, Dr. Scott Gottlieb, some states may be “on the cusp of losing control.”

Should that happen, we could see some states close up shop yet again.

Worse, the virus is still infecting about 20,000 people in the U.S. every day.  “The question is ‘can we keep this from getting out of control.’ This is a virus that wants to infect a very large portion of the population,” Gottlieb told CNBC. “They’re on the cusp of losing control of those outbreaks in certain parts of those states. Arizona, Houston, Austin, parts of Florida certainly look very concerning right now.”

The only way to battle the virus is with successful treatments.  Here are the top companies racing to produce those.

Eli Lilly & Co. (LLY)

At the moment, Eli Lilly has two antibody candidates in phase I studies for treating COVID-19. It also began Phase 3 studies with its JAK inhibitor as a potential treatment for hospitalized patients with COVID-19, as well.

AstraZeneca (AZN)

AstraZeneca has an agreement with Oxford University for the development and distribution of a potential recombinant adenovirus vaccine, known as AZD1222 to prevent COVID-19. It is currently being evaluated in a phase II/III study.

Moderna Inc. (MRNA)

“Moderna has finalized the Phase 3 study protocol based on feedback from the U.S. Food and Drug Administration (FDA). The randomized, 1:1 placebo-controlled trial is expected to include approximately 30,000 participants enrolled in the U.S. and is expected to be conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).”